AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that Eric Poma, Ph.D., Chief Executive Officer and Chief Scientific Officer, will present a corporate overview at the Evercore ISI HealthCONx Conference, and the Piper Jaffray 31st Annual Healthcare Conference.
Evercore ISI HealthCONx Conference Date: Tuesday, December 3, 2019 Time: 3:05pm Eastern Time Webcast: Click here for webcast
Piper Jaffray 31st Annual Healthcare Conference Date: Thursday, December 5, 2019 Time: 1:50pm Eastern Time Webcast: Click here for webcast
About Molecular Templates Molecular Templates is a clinical-stage oncology company focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer. We believe our proprietary biologic drug platform technology, referred to as engineered toxin bodies, or ETBs, provides a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics. ETBs utilize a genetically engineered form of Shiga-like Toxin A subunit, or SLTA, a ribosome inactivating bacterial protein, that can be targeted to specifically destroy cancer cells.
